Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GDUFA II: Priority Reviews Considered For Some ANDAs

This article was originally published in The Pink Sheet Daily

Executive Summary

New pathway could restart argument between industry and FDA over what qualifies for expedited review.

Advertisement

Related Content

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
GDUFA II: FDA Prefers A ‘Manageable Number of High-Impact Changes’
Copaxone And Complex Generics: Difficult-To-Copy Does Not Mean Impossible
ANDA Expedited Review Criteria MaPPed Out By FDA Generic Drug Office

Topics

Advertisement
UsernamePublicRestriction

Register